Accepted for Publication: May 6, 2012.
Published Online: July 23, 2012. doi:10.1001/archinternmed.2012.2713
Author Contributions:Study concept and design: Lalmohamed, Vestergaard, de Boer, Leufkens, and de Vries. Acquisition of data: Lalmohamed, Vestergaard, and de Vries. Analysis and interpretation of data: Lalmohamed, Klop, Grove, de Boer, Leufkens, van Staa, and de Vries. Drafting of the manuscript: Lalmohamed and de Vries. Critical revision of the manuscript for important intellectual content: Lalmohamed, Vestergaard, Klop, Grove, de Boer, Leufkens, van Staa, and de Vries. Statistical analysis: Lalmohamed, Vestergaard, and de Boer. Obtained funding: Lalmohamed and Vestergaard. Administrative, technical, and material support: Vestergaard, Leufkens, and de Vries. Study supervision: Vestergaard, Grove, de Boer, Leufkens, van Staa, and de Vries.
Financial Disclosure: The Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, which employs Mr Lalmohamed, Ms Klop, and Drs de Boer, Leufkens, van Staa, and de Vries, has received unrestricted funding for pharmacoepidemiologic research from GlaxoSmithKline, the private-public–funded Top Institute Pharma (www.tipharma.nl; includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health.
Funding/Support: This study was supported by grant 017.007.010 from the Netherlands Organization for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek, The Hague, the Netherlands).